| Page 1727 | Kisaco Research
 

Elliot Nickbarg

Principal Scientist
MSD Research Laboratories

Elliot Nickbarg received a bachelor’s degree from the University of Chicago and a doctorate in Chemistry from Harvard University. Originally from western New York, he has have lived in the Boston area for a while, working at both large and small biotech and pharmaceutical companies. He joined Merck in 2010 as part of the Schering Plough merger. 

Elliot Nickbarg

Principal Scientist
MSD Research Laboratories

Elliot Nickbarg

Principal Scientist
MSD Research Laboratories

Elliot Nickbarg received a bachelor’s degree from the University of Chicago and a doctorate in Chemistry from Harvard University. Originally from western New York, he has have lived in the Boston area for a while, working at both large and small biotech and pharmaceutical companies. He joined Merck in 2010 as part of the Schering Plough merger. 

 

Dr Alex Morrow

Secretariat to the International Research Consortium on Animal Health (SIRCAH)

Dr Alex Morrow

Secretariat to the International Research Consortium on Animal Health (SIRCAH)

Dr Alex Morrow

Secretariat to the International Research Consortium on Animal Health (SIRCAH)
 

Dr Frauke Neuser

Associate Director, Science & Innovation Communications
Procter & Gamble

Dr Frauke Neuser

Associate Director, Science & Innovation Communications
Procter & Gamble

Dr Frauke Neuser

Associate Director, Science & Innovation Communications
Procter & Gamble
 

Sindhya Valloppillil

CEO & CoFounder
Skin Dossier

Sindhya is currently the CEO & Founder of a stealth-mode beauty personalization startup. Previously, she was Co-founder & CEO of SkinGenie, the world's first beauty tech company offering AI & DNA-based personalization. Sindhya is an award-winning marketing, strategy & innovations beauty executive with 20 years of experience working at top global beauty companies such as L'Oreal, L Brands, J&J and Zirh. She has also worked as an Adjunct Marketing Professor at Berkeley College.

Sindhya Valloppillil

CEO & CoFounder
Skin Dossier

Sindhya Valloppillil

CEO & CoFounder
Skin Dossier

Sindhya is currently the CEO & Founder of a stealth-mode beauty personalization startup. Previously, she was Co-founder & CEO of SkinGenie, the world's first beauty tech company offering AI & DNA-based personalization. Sindhya is an award-winning marketing, strategy & innovations beauty executive with 20 years of experience working at top global beauty companies such as L'Oreal, L Brands, J&J and Zirh. She has also worked as an Adjunct Marketing Professor at Berkeley College. She is currently a Venture Partner for NextGen Venture Partners, an Advisor to the Ember Company, Shadoka Ventures and the Global Wellness Institute. Her writing about the beauty and consumer startup ecosystem has been published in Fast Company, Yahoo Finance, Business Insider, Business of Fashion, Pando Daily, and AlleyWatch. She recently published a whitepaper on the Bull & Bear Case for Personalization in BeautyMatter.

 

Lucile Battail

Fondatrice
LABOTÉ

Lucile is a pharmacist. She started to make magic potions in a playhouse in its parents’ garden when she was only 6. 

After a PHD at the Paris faculty of pharmacy, she studied at HEC Paris. 4 years ago, she decided to create a new brand of fresh and customized cosmetics when she realised that  she was not the only one desperately searching for a good cream and so the industrial « one size fits all » was over. 

Lucile Battail

Fondatrice
LABOTÉ

Lucile Battail

Fondatrice
LABOTÉ

Lucile is a pharmacist. She started to make magic potions in a playhouse in its parents’ garden when she was only 6. 

After a PHD at the Paris faculty of pharmacy, she studied at HEC Paris. 4 years ago, she decided to create a new brand of fresh and customized cosmetics when she realised that  she was not the only one desperately searching for a good cream and so the industrial « one size fits all » was over. 

It took 2 years of research and one patent pending to totally rethink the cosmetic value chain to provide, in 4 easy steps, real custom skincare formulas. Laboté's products are designed by expert pharmacists after a personal consultation. They are made on demand (and in 7 minutes only) in our on-site labs thanks to our patented cold formulation process.

Online sales started in February 2017 and the first lab-shop opened its doors at 11 rue Madame in Paris in April 2017. Pop-ups are born in 2018 and 2019 at Galeries Lafayette, at BHV, at MERCI and Bon Marché. The second shop will open in November. 

 

Gerry Stopps

Sales & Marketing Director
Omega Ingredients

Gerry Stopps, Sales and Marketing Director at Omega Ingredients is a self-motivated sales professional with a solid technical background with 30 years’ experience with international flavour companies. His clients includes some of the world’s best known blue-chip companies along with some of the fastest growing young ventures in the Food and Beverage sector.

Gerry Stopps

Sales & Marketing Director
Omega Ingredients

Gerry Stopps

Sales & Marketing Director
Omega Ingredients

Gerry Stopps, Sales and Marketing Director at Omega Ingredients is a self-motivated sales professional with a solid technical background with 30 years’ experience with international flavour companies. His clients includes some of the world’s best known blue-chip companies along with some of the fastest growing young ventures in the Food and Beverage sector.

 

Darshana Zaveri

Managing Partner
Catalyst Health Ventures

Darshana Zaveri

Managing Partner
Catalyst Health Ventures

Darshana Zaveri

Managing Partner
Catalyst Health Ventures
 

Mary Kerr

Former CEO & Co-Founder
KaNDy Therapeutics

Mary Kerr has served as Chief Executive Officer (CEO) of NeRRe Therapeutics, a privately funded UK Biotech since 2015, and a non-executive independent director at Galapagos NV since 2016. In 2017 Mary co-founded and was CEO of KaNDy Therapeutics until the company was acquired by Bayer in September 2020 for an upfront consideration of $425 million and additional potential development, regulatory and sales milestone payments.

Mary Kerr

Former CEO & Co-Founder
KaNDy Therapeutics

Mary Kerr

Former CEO & Co-Founder
KaNDy Therapeutics

Mary Kerr has served as Chief Executive Officer (CEO) of NeRRe Therapeutics, a privately funded UK Biotech since 2015, and a non-executive independent director at Galapagos NV since 2016. In 2017 Mary co-founded and was CEO of KaNDy Therapeutics until the company was acquired by Bayer in September 2020 for an upfront consideration of $425 million and additional potential development, regulatory and sales milestone payments. Before her career in Biotech, Mary held a range of senior leadership roles at GlaxoSmithKline and heritage companies for more than 20 years, including Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. Mary was a founding member and on the Corporate Executive team of ViiV Healthcare, where she led the European business. She has spent most of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. Mary gained a BSc and Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit, and has an MBA from the University of Kingston.

 

Laurie Cooke

President & CEO
Healthcare Businesswomen’s Association

Laurie Cooke

President & CEO
Healthcare Businesswomen’s Association

Laurie Cooke

President & CEO
Healthcare Businesswomen’s Association
 

Patricia Mechael

Co-Founder and Policy Lead
HealthEnabled

Patricia Mechael

Co-Founder and Policy Lead
HealthEnabled

Patricia Mechael

Co-Founder and Policy Lead
HealthEnabled